to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism

18-Sep-2009 - Netherlands

to-BBB and MedImmune are starting a research program to evaluate to-BBB’s proprietary G-Technology™ to safely deliver drugs to the brain.

Many brain diseases cannot be treated with today’s disease modifying biologics due to the presence of the neuroprotective blood-brain barrier (BBB). to-BBB’s G-Technology is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated liposomes. The G-Technology has shown proof of concept in different disease models for pain, viral encephalitis and brain tumors, based on which MedImmune will now evaluate the technology in its own pharmacodynamic models.

“We are looking forward to working with MedImmune” says Pieter Gaillard, CSO of to-BBB “The project will be of great value to further validate our brain delivery platform and work towards therapies for devastating brain diseases”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances